N-acetylcysteine inhibit biofilms produced by Pseudomonas aeruginosa.
BACKGROUND
Pseudomonas aeruginosa is a common pathogen in chronic respiratory tract infections. It typically makes a biofilm, which makes treatment of these infections difficult. In this study, we investigated the inhibitory effects of N-acetylcysteine (NAC) on biofilms produced by P. aeruginosa.


RESULTS
We found that minimum inhibitory concentrations (MICs) of NAC for most isolates of P. aeruginosa were 10 to 40 mg/ml, the combination of NAC and ciprofloxacin (CIP) demonstrated either synergy (50%) or no interaction (50%) against the P. aeruginosa strains. NAC at 0.5 mg/ml could detach mature P. aeruginosa biofilms. Disruption was proportional to NAC concentrations, and biofilms were completely disrupted at 10 mg/ml NAC. Analysis using COMSTAT software also showed that PAO1 biofilm biomass decreased and its heterogeneity increased as NAC concentration increased. NAC and ciprofloxacin showed significant killing of P. aeruginosa in biofilms at 2.5 mg/ml and > 2 MIC, respectively (p < 0.01). NAC-ciprofloxacin combinations consistently decreased viable biofilm-associated bacteria relative to the control; this combination was synergistic at NAC of 0.5 mg/ml and CIP at 1/2MIC (p < 0.01). Extracellular polysaccharides (EPS) production by P. aeruginosa also decreased by 27.64% and 44.59% at NAC concentrations of 0.5 mg/ml and 1 mg/ml.


CONCLUSIONS
NAC has anti-bacterial properties against P. aeruginosa and may detach P. aeruginosa biofilms. Use of NAC may be a new strategy for the treatment of biofilm-associated chronic respiratory infections due to P. aeruginosa, although it would be appropriate to conduct clinical studies to confirm this.
Zhao
Tiemei
T
Department of Respiratory diseases, Chinese PLA General Hospital, Beijing, China.
Liu
Youning
Y
D000111:Acetylcysteine / Q000494:pharmacology*; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D018441:Biofilms / Q000187:drug effects* / Q000254:growth & development*; D018533:Biomass; D002939:Ciprofloxacin / Q000494:pharmacology; D015169:Colony Count, Microbial; D004347:Drug Interactions; D006801:Humans; D008826:Microbial Sensitivity Tests; D050296:Microbial Viability; D011550:Pseudomonas aeruginosa / Q000187:drug effects* / Q000254:growth & development / Q000502:physiology*
D000900:Anti-Bacterial Agents; D002939:Ciprofloxacin; D000111:Acetylcysteine
J Infect. 1981 Dec;3(4):353-9
6821097
Chest. 1998 Dec;114(6):1594-8
9872194
J Antimicrob Chemother. 2000 Jul;46(1):69-72
10882691
Eur Respir J. 1996 Aug;9(8):1601-4
8866579
J Clin Microbiol. 1989 Sep;27(9):2039-41
2476465
J Antimicrob Chemother. 1997 May;39(5):643-6
9184365
Eur Respir J. 1989 Mar;2(3):234-7
2659383
Lancet. 1993 Apr 24;341(8852):1065-9
7682274
Trends Microbiol. 2001 Jan;9(1):34-9
11166241
Respirology. 2007 Jan;12(1):81-7
17207030
J Clin Microbiol. 1995 Jul;33(7):1842-6
7665657
Pol J Microbiol. 2009;58(3):261-7
19899620
Antimicrob Agents Chemother. 1993 Mar;37(3):613-5
8460929
APMIS. 2007 Aug;115(8):891-9
17696944
Acta Otolaryngol. 2004 Aug;124(6):726-31
15515498
Int J Antimicrob Agents. 2003 Oct;22 Suppl 2:95-100
14527779
J Clin Microbiol. 1977 Jan;5(1):58-61
401831
Thorax. 2002 Jan;57(1):15-9
11809984
Zhonghua Jie He He Hu Xi Za Zhi. 2001 Jun;24(6):339-41
11802984
Infection. 2007 Jun;35(3):143-9
17565454
Microbiology (Reading). 2000 Oct;146 ( Pt 10):2395-2407
11021916
Appl Environ Microbiol. 2003 Aug;69(8):4814-22
12902275
Eur Respir J. 2000 Aug;16(2):253-62
10968500
Infect Immun. 1991 Feb;59(2):471-7
1898904
Am J Med. 1995 Dec 29;99(6A):26S-30S
8585531
Clin Infect Dis. 2008 Dec 15;47(12):1526-33
18990062
N Engl J Med. 2002 Oct 3;347(14):1110-1
12362015